Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP01 open-label extension in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
ACTRN12625000246482Phase 2Recruiting
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Avalyn Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of AP01. Started Apr 2025; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on ACTRN12625000246482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000246482.